Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)-MedSci.cn

Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)

Pietrantonio, F; Morano, F; Niger, M; Ghelardi, F; Chiodoni, C; Palazzo, M; Brambilla, N; Benincasa, E; Giacovelli, G; Vitalini, C; Girolami, F; Rovati, LC

ANNALS OF ONCOLOGY, 2023; 34 (): S452

科室
- - 订阅+
  - 更多科室
工具
服务